“At Intellia, we continue to build the broadest and deepest genome editing platform for developing potentially curative treatments for severe diseases,” said Intellia President and Chief Executive Officer John Leonard, M.D. “We are quite pleased to share the expansion of our ex vivo toolbox to include base editing, which perfectly complements our existing cell engineering and editing capabilities. We believe our scientific innovation in advancing this novel technology will support our development of a broad portfolio of cancer and autoimmune therapies.”
Presentation Details
| Title: |
“Special Edition: Expanding Intellia’s Toolbox with Base Editing” |
| Session: |
Gene Editing |
| Date & Time: |
March 25, 2021 from 9:30am – 12:30 pm EST |
| Presenting Author: |
Christian Dombrowski, Sr. Director of Intellia Therapeutics’ Gene Editing Platform Group |
Data Summary:
Intellia has developed a therapeutically relevant cytosine deaminase base editor that is equipotent to Cas9 for T cell editing.
The combination of Intellia’s base editor with its proprietary cell engineering process achieved >90% T cell editing efficiency while maintaining translocations at background levels.
The presentation can be found on the Scientific Publications & Presentations page of the Intellia Therapeutics website.
| Title: |
“New Era of Genome Editing: In Vivo, Liver-Directed CRISPR Candidates for Rare Diseases” |
| Session: |
Nucleic Acid Clinical Programs |
| Date & Time: |
March 26, 2021 from 2:30pm – 5:30pm EST |
| Presenting Author: |
Laura Sepp-Lorenzino, Ph.D., Chief Scientific Officer at Intellia Therapeutics |
Intellia Therapeutics
Intellia Therapeutics is a clinical-stage genome editing company focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential by both producing therapeutics that permanently edit and correct disease-associated to transform medicine genes in the human body with a single treatment course, and creating enhanced engineered cells that can treat oncological and immunological diseases. Intellia’s combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create new classes of therapeutic products. Learn more about Intellia and CRISPR/Cas9 at intelliatx.com.
Prohost Observations
We believe that the CRiSPR gene-editing firms, including the three firms included in the Prohost Portfolio, will be the players in the most important roles for the future advancement of treating diseases &/or bringing cures into the drug market. Investors in these firms’ stocks should consider this fact, especially with the promise of the creation of cures for hereditary and non-hereditary genetic-derived diseases.
To read more about Intellia Therapeutics please click here.
Intellia Therapeutics’ Important Current Presentations
Current Presentations from Intellia Therapeutics
Intellia Therapeutics (NTLA) is presenting the first preclinical data set on its novel cytosine deaminase base editor technology at the seventh Cold Spring Harbor Laboratory (CSHL) virtual scientific meeting on Nucleic Acid Therapies.
The data shows how the Company’s proprietary base editors can expand its genome editing capabilities by enabling the introduction of multiple gene knockouts simultaneously with no detectable increase in translocation above background levels. The meeting is being held virtually from March 24-26, 2021.
From the President & CEO of Intellia Therapeutics
Other Articles